Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. Kenfield SA, et al. Among authors: friedlander t. Cancer Med. 2021 Nov;10(22):8058-8070. doi: 10.1002/cam4.4324. Epub 2021 Oct 12. Cancer Med. 2021. PMID: 34636156 Free PMC article. Clinical Trial.
Novel hormonal approaches in prostate cancer.
Friedlander TW, Ryan CJ. Friedlander TW, et al. Curr Oncol Rep. 2009 May;11(3):227-34. doi: 10.1007/s11912-009-0032-4. Curr Oncol Rep. 2009. PMID: 19336015 Review.
Editorial comment.
Friedlander TW, Ryan CJ. Friedlander TW, et al. J Urol. 2010 Nov;184(5):1976. doi: 10.1016/j.juro.2010.06.161. J Urol. 2010. PMID: 20884031 No abstract available.
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Friedlander TW, et al. Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2. Urol Oncol. 2012. PMID: 20884247 Clinical Trial.
Targeting the androgen receptor.
Friedlander TW, Ryan CJ. Friedlander TW, et al. Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Urol Clin North Am. 2012. PMID: 23084523 Review.
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Kim W, et al. Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21. Clin Cancer Res. 2014. PMID: 25336698 Free PMC article. Clinical Trial.
117 results